此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Intertransverse Process Block Versus Transversus Abdominis Plane Block After Robot, Laparoscopic Hepatectomy

2026年11月12日 更新者:Yonsei University

Somatic and Visceral Analgesic Efficacy and Opioid-Sparing Effect of Ultrasound-Guided Intertransverse Process Block Versus Transversus Abdominis Plane Block After Robot, Laparoscopic Hepatectomy: A Randomized Controlled Trial

This prospective randomized controlled study will compare the postoperative analgesic efficacy and opioid-sparing effect of ultrasound-guided bilateral intertransverse process block (ITPB) with bilateral transversus abdominis plane (TAP) block combined with rectus sheath block in adults undergoing elective robotic or laparoscopic hepatectomy. A total of 64 participants will be randomly assigned in a 1:1 ratio to the ITPB group or the TAP block group. Both groups will receive standardized general anesthesia and multimodal postoperative analgesia, including patient-controlled analgesia. The primary outcome is cumulative opioid consumption during the first 24 hours after surgery, expressed as intravenous morphine equivalents. Secondary outcomes include cumulative opioid consumption through 72 hours, incisional and visceral pain intensity, shoulder pain, sensory block distribution, rescue analgesic use, quality of recovery, postoperative recovery parameters, and adverse events.

研究概览

详细说明

Eligible adults scheduled for elective robotic or laparoscopic hepatectomy under general anesthesia will be screened according to the predefined inclusion and exclusion criteria. After written informed consent is obtained, participants will receive preoperative education regarding pain assessment and patient-controlled analgesia and will complete the baseline Quality of Recovery-15 assessment.

On the day of surgery, participants will be randomly assigned in a 1:1 ratio using a computer-generated randomization sequence with allocation concealed using sealed opaque envelopes.

Before induction of general anesthesia, the assigned regional block will be performed under mild sedation and real-time ultrasound guidance by an experienced anesthesiologist. Participants assigned to the ITPB group will receive bilateral intertransverse process block at the T6-7 and T9-10 levels. Participants assigned to the comparator group will receive bilateral oblique subcostal transversus abdominis plane block combined with rectus sheath block.

Both groups will receive 0.3% ropivacaine at four injection sites, with 15 mL administered at each site, for a total volume of 60 mL and a total dose of 180 mg. In participants weighing 60 kg or less, the total dose will be reduced to remain within 3 mg/kg.

Sensory block will be assessed using cold and pinprick testing at 5, 15, and 30 minutes after block placement. Participants, anesthesia and postoperative care providers, postoperative outcome assessors, and the statistical analyst will remain masked to treatment allocation. Because of the nature of the procedure, the anesthesiologist performing the assigned regional block cannot be masked and will not participate in subsequent postoperative management or outcome assessment.

All participants will receive standardized general anesthesia and multimodal postoperative analgesia, including patient-controlled analgesia. Postoperative outcomes will be assessed at 2, 4, 6, 12, 24, 48, and 72 hours after surgery and at discharge as applicable.

Blood samples will be collected at 35 minutes, 60 minutes, 90 minutes, 2 hours, 6 hours, and 25 hours after completion of the regional block.

研究类型

介入性

注册 (估计的)

64

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Bon-Nyeo Koo, Professor
  • 电话号码:+82-10-6208-5797
  • 邮箱:KOOBN@yuhs.ac

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

19年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

Adults aged 19 years or older. American Society of Anesthesiologists physical status I-III. Scheduled for elective robotic or laparoscopic hepatectomy under general anesthesia.

Able to understand and use patient-controlled analgesia (PCA). Able to understand the purpose and procedures of the study and voluntarily provide written informed consent.

Exclusion Criteria:

History of allergy to local anesthetics or study medications. Coagulopathy, defined as INR > 1.5 or platelet count < 70,000/μL, or current anticoagulant use.

Infection at the regional block site. History of chronic pain or chronic opioid use for 3 months or longer. History of drug or alcohol abuse or dependence. Severe cardiopulmonary dysfunction or neurological disease. Cognitive impairment or psychiatric disease preventing cooperation with pain assessment, including the Numerical Rating Scale (NRS).

Body mass index (BMI) < 18 or > 35 kg/m². Pregnancy or breastfeeding. Scar at the block site that interferes with ultrasound visualization or local anesthetic spread.

History of abdominal surgery.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:ITPB Group

Participants will receive ultrasound-guided bilateral intertransverse process block at the T6-7 and T9-10 levels before induction of general anesthesia.

Before induction of general anesthesia and under mild sedation, bilateral intertransverse process block will be performed under real-time ultrasound guidance at the T6-7 and T9-10 levels. Ropivacaine 0.3%, 15 mL, will be administered at each of four injection sites, for a total volume of 60 mL and a total dose of 180 mg. For participants weighing 60 kg or less, the total dose will be reduced to remain within 3 mg/kg.

其他名称:
  • ITPB
  • Intertransverse Process Block
有源比较器:TAP + Rectus Sheath Block Group

Participants will receive ultrasound-guided bilateral oblique subcostal transversus abdominis plane block combined with rectus sheath block before induction of general anesthesia.

Before induction of general anesthesia and under mild sedation, bilateral oblique subcostal transversus abdominis plane block combined with rectus sheath block will be performed under real-time ultrasound guidance. Ropivacaine 0.3%, 15 mL, will be administered at each of four injection sites, for a total volume of 60 mL and a total dose of 180 mg. For participants weighing 60 kg or less, the total dose will be reduced to remain within 3 mg/kg.

其他名称:
  • TAP块
  • 腹横肌平面阻滞
  • Rectus Sheath Block

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Cumulative Postoperative Opioid Consumption at 24 Hours
大体时间:From the end of surgery through 24 hours postoperatively

Cumulative opioid consumption during the first 24 hours after surgery will be calculated by converting opioid doses administered through patient-controlled analgesia and rescue analgesia to intravenous morphine equivalents and summing the converted doses.

From the end of surgery through 24 hours postoperatively

次要结果测量

结果测量
措施说明
大体时间
Cumulative Postoperative Opioid Consumption at Additional Time Points
大体时间:At 2, 4, 6, 12, 48, and 72 hours postoperatively.

Cumulative postoperative opioid consumption at each specified time point will be calculated by converting opioid doses administered through patient-controlled analgesia and rescue analgesia to intravenous morphine equivalents.

At 2, 4, 6, 12, 48, and 72 hours postoperatively.
Incisional Pain Intensity
大体时间:At 2, 4, 6, 12, 24, 48, and 72 hours postoperatively.

Incisional or somatic pain intensity will be assessed separately using the Numeric Rating Scale (NRS).

At 2, 4, 6, 12, 24, 48, and 72 hours postoperatively.
Visceral Pain Intensity
大体时间:At 2, 4, 6, 12, 24, 48, and 72 hours postoperatively.

Deep or visceral abdominal pain intensity will be assessed separately using the Numeric Rating Scale (NRS). Participants will be instructed preoperatively to distinguish deep or generalized abdominal pain from pain at the incision site.

At 2, 4, 6, 12, 24, 48, and 72 hours postoperatively.
Shoulder Pain Incidence and Intensity Assessed Using the Numeric Rating Scale (NRS)
大体时间:At 2, 4, 6, 12, 24, 48, and 72 hours postoperatively.

The presence of postoperative shoulder pain associated with diaphragmatic irritation will be recorded, and its intensity will be assessed using the Numeric Rating Scale (NRS).

At 2, 4, 6, 12, 24, 48, and 72 hours postoperatively.
Extent and Distribution of Sensory Block
大体时间:At 5, 15, and 30 minutes after completion of the regional block.

Sensory block will be assessed using cold and pinprick testing. The highest and lowest blocked dermatomes, the total number of blocked dermatomes, anterior and posterior spread, and the presence or absence of posterior/paravertebral sensory block will be recorded.

At 5, 15, and 30 minutes after completion of the regional block.
Pain Intensity at Rest and During Coughing or Movement
大体时间:At 2, 4, 6, 12, 24, 48, and 72 hours postoperatively.

Pain intensity at rest and during coughing or movement will be assessed using the Numeric Rating Scale (NRS).

At 2, 4, 6, 12, 24, 48, and 72 hours postoperatively.
Time to First Rescue Analgesic Request
大体时间:Up to 72 hours after surgery.

Time to the first request for rescue analgesia will be recorded.

Up to 72 hours after surgery.
Frequency of Rescue Analgesic Administration
大体时间:During the first 48 hours postoperatively.

The number of rescue analgesic administrations during the first 48 postoperative hours will be recorded.

During the first 48 hours postoperatively.
Quality of Recovery-15 (QoR-15) Score
大体时间:On postoperative day 1, postoperative day 3, and at hospital discharge (between postoperative days 4 and 21).

Quality of recovery will be assessed using the Quality of Recovery-15 (QoR-15) questionnaire on postoperative day 1, postoperative day 3, and at hospital discharge (between postoperative days 4 and 21).

On postoperative day 1, postoperative day 3, and at hospital discharge (between postoperative days 4 and 21).
Time to First Flatus
大体时间:From surgery until first postoperative flatus, assessed through postoperative day 3 (POD 3).

The time to first postoperative flatus will be recorded.

From surgery until first postoperative flatus, assessed through postoperative day 3 (POD 3).
Time to First Ambulation
大体时间:From surgery until first postoperative ambulation, assessed through postoperative day 3 (POD 3).

The time to first postoperative ambulation will be recorded.

From surgery until first postoperative ambulation, assessed through postoperative day 3 (POD 3).
Postoperative Length of Hospital Stay
大体时间:From surgery through hospital discharge, an expected average of approximately 8 days.

Postoperative length of hospital stay will be recorded as the number of calendar days from the date of surgery to hospital discharge. The date of surgery will be defined as postoperative day (POD) 0.

From surgery through hospital discharge, an expected average of approximately 8 days.
Opioid-Related Adverse Events
大体时间:At 2, 4, 6, 12, 24, 48, and 72 hours postoperatively.

The incidence of opioid-related adverse events, including nausea, vomiting, excessive sedation, respiratory depression, pruritus, urinary retention, and reduced gastrointestinal motility, will be assessed.

At 2, 4, 6, 12, 24, 48, and 72 hours postoperatively.
Block-Related Complications
大体时间:From regional block placement through 72 hours postoperatively.

The incidence of block-related complications, including pneumothorax, pleural puncture, hematoma, infection, local anesthetic systemic toxicity, nerve injury, lower-limb weakness, unintended neuraxial block, and intra-abdominal organ injury, will be assessed.

From regional block placement through 72 hours postoperatively.
Comprehensive Complication Index (CCI)
大体时间:At hospital discharge, an expected average of approximately 8 days after surgery.

Postoperative complications will be assessed using the Comprehensive Complication Index (CCI) through hospital discharge.

At hospital discharge, an expected average of approximately 8 days after surgery.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年10月19日

初级完成 (估计的)

2028年4月22日

研究完成 (估计的)

2028年9月25日

研究注册日期

首次提交

2026年10月5日

首先提交符合 QC 标准的

2026年11月12日

首次发布 (实际的)

2026年11月16日

研究记录更新

最后更新发布 (实际的)

2026年11月16日

上次提交的符合 QC 标准的更新

2026年11月12日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅